About Free fatty acid receptor 2
Free fatty acid receptor 2 (FFAR2) is a protein
from Homo sapiens identified by UniProt accession
O15552, 330 residues long.
MolForge cross-references it against 0 known binders and
326 disease associations.
Target properties
| Protein name | Free fatty acid receptor 2 |
| UniProt accession | O15552 |
| Gene | FFAR2 |
| Organism | Homo sapiens |
| Length | 330 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (326)
Diseases linked to this target (Open Targets).
- neutrophil count · score 0.36
- monocyte percentage of leukocytes · score 0.34
- glioblastoma multiforme · score 0.25
- hemoglobin measurement · score 0.17
- Red cell distribution width · score 0.17
- mean corpuscular hemoglobin concentration · score 0.17
- mean corpuscular hemoglobin · score 0.17
- mean corpuscular volume · score 0.12
- transferrin saturation measurement · score 0.12
- serum iron measurement · score 0.12
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O15552-F1 | alphafold | PREDICTED | 88.07 | — |
Amino-acid sequence (330 residues)
MLPDWKSSLI LMAYIIIFLT GLPANLLALR AFVGRIRQPQ PAPVHILLLS LTLADLLLLL LLPFKIIEAA SNFRWYLPKV VCALTSFGFY SSIYCSTWLL AGISIERYLG VAFPVQYKLS RRPLYGVIAA LVAWVMSFGH CTIVIIVQYL NTTEQVRSGN EITCYENFTD NQLDVVLPVR LELCLVLFFI PMAVTIFCYW RFVWIMLSQP LVGAQRRRRA VGLAVVTLLN FLVCFGPYNV SHLVGYHQRK SPWWRSIAVV FSSLNASLDP LLFYFSSSVV RRAFGRGLQV LRNQGSSLLG RRGKDTAEGT NEDRGVGQGE GMPSSDFTTE
Explore Free fatty acid receptor 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets